Exelixis, Inc. (NASDAQ:EXEL) Receives $49.29 Average Target Price from Analysts

Shares of Exelixis, Inc. (NASDAQ:EXEL) have earned an average rating of “Hold” from the nineteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $49.7857.

Several research analysts have issued reports on the company. Leerink Partners lowered Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 price target on the stock. in a report on Thursday. Morgan Stanley upped their target price on Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 23rd. Citizens Jmp increased their target price on Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Wednesday, June 24th. TD Cowen lifted their price target on shares of Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, HC Wainwright restated a “buy” rating and set a $56.00 price target on shares of Exelixis in a research note on Thursday, July 2nd.

Key Headlines Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis reported second-quarter EPS of $0.91, ahead of the $0.85-$0.86 analyst consensus and up from $0.75 a year earlier. Revenue rose 10.6% year over year to approximately $628.7 million, while the company continues to benefit from its established cabozantinib business. Exelixis Q2 earnings
• Positive Sentiment: The company launched a new Phase 3 trial testing zanzalintinib in residual colorectal cancer, expanding the potential market for its pipeline and providing another long-term growth catalyst. Exelixis colorectal cancer trial
• Positive Sentiment: TD Cowen reaffirmed a Buy rating and a $55 price target, citing resilience in cabozantinib, cost discipline and upside from zanzalintinib despite near-term guidance pressure.
• Neutral Sentiment: Stifel raised its price target from $47 to $51 but retained a Hold rating. Its target remains below the recent trading level, suggesting limited near-term upside in the analyst’s view.
• Negative Sentiment: Exelixis lowered the midpoint of its 2026 revenue outlook by $50 million, primarily because the NET launch has been slower than expected. Although the EPS beat was encouraging, the revenue miss and reduced outlook are weighing on growth expectations. Exelixis 2026 guidance
• Negative Sentiment: Leerink Partners downgraded EXEL from Outperform to Market Perform and set a $52 price target, below the recent share price. Leerink Partners downgrade
• Negative Sentiment: Zacks Research maintains a Strong Sell rating and made small reductions to its FY2026-FY2028 EPS forecasts, including a FY2026 estimate of $3.12 versus the broader consensus of $3.15.

Insider Activity at Exelixis

In related news, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the sale, the chief financial officer owned 952,317 shares in the company, valued at $47,615,850. This represents a 3.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jack L. Wyszomierski sold 3,925 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $50.55, for a total transaction of $198,408.75. Following the completion of the transaction, the director directly owned 284,384 shares in the company, valued at approximately $14,375,611.20. The trade was a 1.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 130,824 shares of company stock valued at $6,555,231 over the last quarter. 2.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Exelixis in the 2nd quarter valued at $1,581,991,000. AQR Capital Management LLC boosted its holdings in Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after acquiring an additional 4,477,029 shares during the last quarter. Norges Bank purchased a new position in Exelixis during the 4th quarter worth $106,460,000. Bank of New York Mellon Corp bought a new stake in shares of Exelixis in the 2nd quarter worth $107,803,000. Finally, UBS Group AG grew its stake in shares of Exelixis by 100.1% in the 3rd quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company’s stock worth $109,654,000 after acquiring an additional 1,328,087 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $54.07 on Monday. The firm has a market capitalization of $13.59 billion, a P/E ratio of 17.00, a P/E/G ratio of 1.63 and a beta of 0.44. The firm’s 50-day moving average price is $54.17 and its 200-day moving average price is $47.97. Exelixis has a 1-year low of $33.76 and a 1-year high of $57.57.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. During the same period last year, the business posted $0.75 EPS. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. Equities research analysts forecast that Exelixis will post 3.15 EPS for the current year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.